Brain Cancer

According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”

Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.

Because EVA1 is not expressed in normal cells, there may be less toxicity when targeting it to eliminate glioblastoma-initiating cells.

Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were the 3 most prominent ADCs in EGFR-amplified glioblastoma.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Data from a phase 1 trial demonstrate the safety and feasibility of administering chlorotoxin-based cellular therapy to those with recurrent glioblastoma.

Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.

A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.

While more work must be done to minimize toxicity, antibody-drug conjugates have demonstrated benefits for patients with glioblastoma.

Interim data from the phase 1b CLOVER-2 trial evaluating iopofosine I 131 in children and adults with high-grade glioma supported the FDA’s decision.

The evaluation of MT-125’s safety and preliminary activity in glioblastoma is underway in a phase 1/2 trial.

Data from the phase 3 ROADS trial show significant gains in efficacy without increases in safety concerns following the use of GammaTile.

A patient case of a 76-year-old man with a rare glioblastoma variant showcased the importance of molecular profiling in diagnosing and guiding treatment for brain tumors.

Results from a pilot phase 2 trial showed that all 5 patients who received treatment achieved a response or had stable disease.

Historical standards for H3K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Supporting data for the accelerated approval of dordaviprone come from 5 open-label trials in H3 K27M-mutant diffuse midline glioma.

Updated guidelines from ASTRO recommend various radiation therapy techniques for patients with WHO grade 4 adult-type diffuse glioma.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

The developer plans to share top-line results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.

The safety profile of iopofosine I 131 in the phase 1b CLOVER-2 trial appears consistent with prior reports of the agent.

Andrew Brenner, MD, PhD, discussed rhenium obisbemeda and results from the ReSPECT-GBM trial for patients with glioblastoma.

Jennifer Moliterno, MD, FAANS, discusses effective collaboration strategies with multidisciplinary colleagues to optimize treatment for brain tumors.

The B7-H3 CAR T-cell therapy showed positive survival results for younger patients with diffuse intrinsic pontine glioma in a phase 1 trial.

Jennifer Moliterno, MD, FAANS, highlights post-operative complications that may arise after neurosurgery.